Arcus Biosciences

RCUS · NYSE

$23.75+$1.61 (+7.27%)TodayMarket closed · Oct 20, 7:55 PM ET

Prev close $22.14

About RCUS

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of immunotherapies. The company is headquartered in Hayward, California and currently employs 601 full-time employees. The company went IPO on 2018-03-15. The firm has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The firm has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The firm is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). The company is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

Employees: 601
Headquarters: Hayward, California
Listed: Mar 15, 2018
Sector: Health Care
Industry: Biotechnology
Website: arcusbio.com

Leadership

Arcus Biosciences executives
Name	Title	Since	Age
Terry Rosen	—	2015	66
Juan Jaen	—	2015	67
Robert Goeltz	—	—	52
Jennifer Jarrett	—	—	54
Carolyn Tang	—	—	46
Richard Markus	—	—	59
Yasunori Kaneko	—	—	71
Dietmar Berger	—	—	62
Linda Higgins	—	—	62
Johanna Mercier	—	—	55
Kathryn Falberg	—	—	64
David Lacey	—	—	72
Nicole Lambert	—	—	51
Patrick Machado	—	—	61
Andrew Perlman	—	—	77
Antoni Ribas	—	—	59

Revenue by product and region

Fiscal year ended Dec 31, 2023: $117.00M total revenue

By product

License and Development Services Revenue$80.00M68.4%
Other Collaboration Revenue$37.00M31.6%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Arcus Biosciences suppliers and customers
Company	Relationship	Country	Correlation
Gilead Sciences GILD	Supplier and customer	US	0.26
Infinity Pharmaceuticals INFI	Supplier and customer	US	0.19
Roche Holding ROG.SW	Supplier and customer	CH	0.19
Wuxi Biologics	Supplier and customer	CN	0.14
Otsuka Holdings	Supplier and customer	JP	-0.19
AstraZeneca AZN.L	Supplier and customer	GB	-0.39
Abmuno Therapeutics LLC	Supplier and customer	US	—
BVF Inc.	Supplier and customer	US	—
Strata Oncology, Inc.	Supplier and customer	US	—

Similar companies

Companies in the same industry as Arcus Biosciences

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.